What is ALLR stock price today?

ALLR (Allarity Therapeutics Inc) stock is trading at $1.77 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ALLR stock going up or down today?

ALLR stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ALLR stock now?

The decision to buy ALLR depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ALLR a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ALLR based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ALLR stock overvalued or undervalued?

Use our DCF valuation calculator to determine if ALLR is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is ALLR's P/E ratio?

P/E ratio data for ALLR will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is ALLR's market cap?

ALLR (Allarity Therapeutics Inc) has a market capitalization of $0.03 billion, making it a small-cap stock.

What is ALLR's price to book ratio?

ALLR trades at a price-to-book (P/B) ratio of 4.07, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does ALLR pay dividends?

ALLR does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ALLR's dividend yield?

ALLR does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ALLR stock a good long-term investment?

ALLR's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ALLR's revenue growth rate?

Revenue growth data for ALLR is available on our dashboard with detailed financial statement analysis.

Profitability metrics for ALLR are available on our dashboard with complete income statement analysis.

What are the risks of investing in ALLR?

Key risks for ALLR include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ALLR compare to its competitors?

Compare ALLR to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ALLR's performance and positioning.

What is ALLR's stock price target for 2026?

Our AI model provides price targets for ALLR based on fundamental analysis: Bull case $2.30 (+30%), Base case $2.04 (+15%), Bear case $1.59 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ALLR?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ALLR. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ALLR's next earnings report?

ALLR reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ALLR - Allarity Therapeutics Inc

NYSE * Health Care * Biotechnology

$1.77

+$0.11 (+6.63%)

About Allarity Therapeutics Inc

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.

ALLR Key Statistics

Market Cap

$28.16M

P/B Ratio

4.07

EPS

$-0.70

Employees

How ALLR Compares to Peers

ALLR is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ALLR(This stock)	$28.16M	N/A	0%	0.0%	-
AMGNAmgen Inc	$183.12B	23.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$166.82B	18.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$110.28B	25.8	0%	0.4%	vs VRTX
REGNRegeneron Pharmaceuticals	$66.98B	15.6	0%	0.3%	vs REGN
BIIBBiogen Inc	$28.61B	20.8	0%	0.1%	vs BIIB

Allarity Therapeutics Inc Company Information

Headquarters: Massachusetts; U.S.A
Website: www.allarity.com
Sector: Health Care
Industry: Biotechnology

ALLR - Allarity Therapeutics Inc

About Allarity Therapeutics Inc

ALLR Key Statistics

How ALLR Compares to Peers

Allarity Therapeutics Inc Company Information

ALLR Lician Score

ALLR Financial Snowflake

Upcoming Events for ALLR